trending Market Intelligence /marketintelligence/en/news-insights/trending/q7-VcLxk2_EV_ObVkRi2RA2 content esgSubNav
In This List

Rhizen drug receives US FDA's orphan drug designation

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Rhizen drug receives US FDA's orphan drug designation

Alembic Pharmaceuticals Ltd. said its associate company Rhizen Pharmaceuticals SA received the U.S. Food and Drug Administration's orphan drug designation for tenalisib.

Tenalisib, also known as RP6530, is a highly selective and orally active dual PI3K delta/gamma inhibitor used for the treatment of peripheral T-cell lymphoma, a type of blood cancer.

The treatment was previously granted the fast track designation by the FDA.